Brilliance

E-Team brings medical device innovation to market

In August of 2009, Stanford University student Ben Cline and D-Rev CEO Krista Donaldson came to the first Sustainable Vision Advanced Invention to Venture (AI2V) workshop in Cambridge. Three years later, their product, Brilliance, a low cost, low maintenance opto-medical device to treat neonatal jaundice, is on the market in India and they are looking to expand to East Africa. Donaldson estimates that early data suggests 13 babies will get treatment per device per month in urban hospitals, which means lives saved and brain damage averted. These results will be closely tracked. Cline’s contribution has been instrumental in early stages of product development of Brilliance. His accomplishments, during later stages, in an advisory role to bring Brilliance to Point-of-Scale are also commendable. His early partnership with D-Rev, was a key factor to this success.

Note: This article has been corrected since its original post to address some factual errors.

Read the New York Times article on Brilliance.

Good news: NCIIA student teams featured in New York Times special on low-cost innovation!

Five NCIIA-funded teams are featured in the New York Times' special on affordable global health innovations. Read about the teams and their innovations, and the challenges faced by student inventors and entrepreneurs:

Ducha Halo portable showerSolar sanitation systemInfantAIR ventilator for newbornsBrilliance jaundice treatment incubator (pictured) • Sproxil anti-counterfeit drug texting system.

 

 

 

 

Licensing deal takes Brilliance's neonatal jaundice treatment to India

Fast Company report on a 2009 NCIIA Sustainable Vision team from Stanford University...

Working with D-Rev, a nonprofit technology incubator based in Palo Alto, the Enabling Effective Management of Neonatal Jaundice in Rural India team signed a licensing agreement with Chennai, India-based Phoenix Medical Systems Private Ltd for the manufacturing and distribution of Brilliance, a novel phototherapy device that enables the treatment of severe neonatal jaundice in low-resource hospitals.

 

 

 

Brilliance from a 2009 Sustainable Vision grantee

This photo is of a neonatal jaundice treatment technology being developed by a Sustainable Vision team from Stanford University working with the non-profit technology incubator, Design Revolution. The Enabling Effective Management of Neonatal Jaundice in Rural India team, a 2009 NCIIA grantee, developed an affordable world-class phototherapy device that will provide effective treatment for newborns in low-income hospitals. Instead of using fluorescent tube or compact fluorescent bulbs, the team’s device uses more efficient, high-intensity blue LEDs that can be supported by a battery backup.

 

Syndicate content